The agreement will assist ArtVentive Medical Group in building its quality systems, regulatory strategy, and securing US Food and Drug Administration (FDA) and European approvals in a timely manner.
In addition, NCRG offers comprehensive services that include, but are not limited to, cardiovascular, endovascular, neurology, pulmonary, and orthopedic areas of healthcare with extensive expertise in clinical studies around the world, IDEs within the USA, and CE mark in Europe.
ArtVentive Medical Group president Jim Graham said that entering into this agreement with NCRG has already had a positive impact on timing for European and FDA approvals.
“This Agreement is essential in achieving the Company’s goal towards regulatory approval and puts us one step closer to getting our products to market quickly,” Graham said.
